The Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol Inhibits Glycogen Phosphorylase
Authors:
- Kayoko NishiKNKayoko Nishi
- Fredric A. GorinFGFredric A. Gorin
- Donal A. WalshDWDonal A. Walsh
- E.Morton BradburyEBE.Morton Bradbury
- Joachim B. SchnierJSJoachim B. Schnier
- 1 February 2001
- journal article
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 386 (2) , 179-187
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Identification of cytosolic aldehyde dehydrogenase 1 from non‐small cell lung carcinomas as a flavopiridol‐binding proteinFEBS Letters, 1999
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.Journal of Clinical Oncology, 1998
- Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cellsInternational Journal of Cancer, 1998
- The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia LinesBlood, 1997
- From Bench Top to Bedside1997
- Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.Proceedings of the National Academy of Sciences, 1996
- Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275Biochemical and Biophysical Research Communications, 1994
- Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275JNCI: Journal of the National Cancer Institute, 1992
- Brain isozyme of glycogen phosphorylase: immunohistologicall localization within the central nervous systemBrain Research, 1990
- McArdle's disease heterozygotes. Metabolic adaptation assessed using 31P-nuclear magnetic resonance.Journal of Clinical Investigation, 1986